Faropenem Daloxate
CAS: 141702-36-5
Ref. 3D-RFA70236
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued |
Product Information
- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
- (5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-tetrahydrofuryl]-2-penem-3-carboxylic acid 5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester
- 1,3-Dioxole, 4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid deriv.
- 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [5R-[3(R*),5α,6α(R*)]]-
- 4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-tetrahydro-2-furanyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5R,6S)-
- A 0026
- Faropenem medoxil
- Faropenem medoxomil
Faropenem is a broad-spectrum anti-infective agent that is an oral prodrug. Faropenem is converted to the active form, daloxate, in the small intestine. The active form of this drug inhibits bacterial growth by binding to DNA-dependent RNA polymerase and preventing transcription and replication. This inhibition prevents the production of proteins necessary for bacterial cell wall synthesis, leading to cell death. Faropenem has been shown to be effective against a wide range of bacteria including Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, and Proteus mirabilis. It also has activity against some strains of Acinetobacter baumannii and Staphylococcus aureus. Resistance to this drug has been observed in some Gram-positive organisms such as Streptococcus pneumoniae and Staphylococcus aureus due to the development of chemical inhibitors
